- Thursday, March 30, 2023
8:30 AM – 8:45 AM CT
Welcome
8:30 AM – 8:45 AM CT
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### 8:45 AM – 9:00 AM CT
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant Immunotherapy
8:45 AM – 9:00 AM CT
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 9:00 AM – 9:15 AM CT
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant Immunotherapy
9:00 AM – 9:15 AM CT
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant ImmunotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor ###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 9:15 AM – 9:30 AM CT
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Discussion
9:15 AM – 9:30 AM CT
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Kansas University Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor ###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### 9:30 AM – 10:30 AM CT
Treatment Options for Certain Patients With Select Advanced Upper Gastrointestinal Cancers. Speaker: John Berry, MD
9:30 AM – 10:30 AM CT
Non-CME Innovation Theater (Sponsored by Merck)
10:30 AM – 10:45 AM CT
Exhibit Hall
10:30 AM – 10:45 AM CT
Exhibit Hall
10:45 AM – 11:00 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined Immunotherapy
10:45 AM – 11:00 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 11:00 AM – 11:15 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Chemotherapy
11:00 AM – 11:15 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - ChemotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor ###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 11:15 AM – 11:30 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DISCUSSION
11:15 AM – 11:30 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Panelist: – Kansas University Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor ###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### 11:30 AM – 12:15 PM CT
Session 3: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing
11:30 AM – 12:15 PM CT
Session 3: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing and Targeted Treatment StrategiesPresenter: – University of Wisconsin, Carbone Cancer Center
Nataliya Uboha, MD, PhD – University of Wisconsin, Carbone Cancer Center ### 904441###Presenter###Associate Professor###University of Wisconsin, Carbone Cancer Center###Presenter: – University of Wisconsin, Carbone Cancer Center
### 12:15 PM – 1:15 PM CT
Evolving Biomarker Landscape in Gastric and Gastroesophageal Junction Adenocarcinomas. Speaker: Stephanie Braun
12:15 PM – 1:15 PM CT
Non-CME Innovation Theater (Sponsored by Astellas)
1:15 PM – 2:00 PM CT
Session 4: Circulating Tumor DNA (ctDNA) in Gastrointestinal Malignancies
1:15 PM – 2:00 PM CT
Session 4: Circulating Tumor DNA (ctDNA) in Gastrointestinal MalignanciesPresenter: – Department of Hematology and Oncology at Cleveland Clinic
Suneel Kamath, MD (he/him/his) – Department of Hematology and Oncology at Cleveland Clinic ### 1886496###Presenter###Assistant Professor of Medicine###Department of Hematology and Oncology at Cleveland Clinic###Presenter: – Department of Hematology and Oncology at Cleveland Clinic
### he/him/his2:00 PM – 2:45 PM CT
6 - Session 5: Integration of Supportive Care
2:00 PM – 2:45 PM CT
Session 5: Integration of Supportive CarePresenter: –
Memorial Sloan Kettering Cancer Center
Andrew Epstein, MD –
Memorial Sloan Kettering Cancer Center ### 1880690###Presenter###Associate Attending ###
Memorial Sloan Kettering Cancer Center###Presenter: –
Memorial Sloan Kettering Cancer Center
### 2:45 PM – 3:15 PM CT
Exhibit Hall
2:45 PM – 3:15 PM CT
Exhibit Hall
3:15 PM – 4:00 PM CT
7 - Session 6: Perspectives on Clinical Trial Development in Anal Cancer
3:15 PM – 4:00 PM CT
Session 6: Perspectives on Clinical Trial Development in Anal CancerPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### - Friday, March 31, 2023
7:45 AM – 8:00 AM CT
Welcome
7:45 AM – 8:00 AM CT
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – University of Chicago
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Co-Chair###Associate Professor of Medicine###University of Chicago###Co-Chair: – University of Chicago
### she/her/hers8:00 AM – 8:15 AM CT
8 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab
8:00 AM – 8:15 AM CT
Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + BevacizumabPresenter: – Fox Chase Cancer Center
Namrata (Neena) Vijayvergia, MD, FACP – Fox Chase Cancer Center ### 1544845###Presenter###Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor###Fox Chase Cancer Center###Presenter: – Fox Chase Cancer Center
### 8:15 AM – 8:30 AM CT
9 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab
8:15 AM – 8:30 AM CT
Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + PanitumumabPresenter: – Department of Hematology and Oncology at Cleveland Clinic
Smitha Krishnamurthi, MD (she/her/hers) – Department of Hematology and Oncology at Cleveland Clinic ### 1691686###Presenter###Associate Professor###Department of Hematology and Oncology at Cleveland Clinic###Presenter: – Department of Hematology and Oncology at Cleveland Clinic
### she/her/hers8:30 AM – 8:45 AM CT
9 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion
8:30 AM – 8:45 AM CT
Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – Fox Chase Cancer Center
Panelist: – Department of Hematology and Oncology at Cleveland Clinic
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Namrata (Neena) Vijayvergia, MD, FACP – Fox Chase Cancer Center ### 1544845###Panelist###Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor###Fox Chase Cancer Center###Panelist: – Fox Chase Cancer Center
### @@@ Smitha Krishnamurthi, MD (she/her/hers) – Department of Hematology and Oncology at Cleveland Clinic ### 1691686###Panelist###Associate Professor###Department of Hematology and Oncology at Cleveland Clinic###Panelist: – Department of Hematology and Oncology at Cleveland Clinic
### she/her/hers8:45 AM – 9:30 AM CT
1 - Session 8: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted Therapies
8:45 AM – 9:30 AM CT
Session 8: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted TherapiesPresenter: – Duke University
John Strickler, MD (he/him/his) – Duke University ### 1422831###Presenter###Associate Professor###Duke University###Presenter: – Duke University
### he/him/his9:30 AM – 10:30 AM CT
Discover a Treatment Option for Locally Advanced or Metastatic Biliary Tract Cancer. Speaker: Dr. Chih-Yi “Andy” Liao
9:30 AM – 10:30 AM CT
Non-CME Innovation Theater (Sponsored by AstraZeneca)
10:30 AM – 10:45 AM CT
Exhibit Hall
10:30 AM – 10:45 AM CT
Exhibit Hall
10:45 AM – 11:30 AM CT
Session 9: Updates from Recent Meetings
10:45 AM – 11:30 AM CT
Session 9: Updates from Recent MeetingsPresenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Presenter###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Presenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 11:30 AM – 11:45 AM CT
8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRT
11:30 AM – 11:45 AM CT
Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRTPresenter: – The University of Texas MD Anderson Cancer Center
Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Presenter###Associate Professor###The University of Texas MD Anderson Cancer Center###Presenter: – The University of Texas MD Anderson Cancer Center
### 11:45 AM – 12:00 PM CT
8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Chemotherapy
11:45 AM – 12:00 PM CT
Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - ChemotherapyPresenter: – Huntsman Cancer Institute at the University of Utah
Heloisa Soares, MD, PhD (she/her/hers) – Huntsman Cancer Institute at the University of Utah ### 1880692###Presenter###Associate Professor###Huntsman Cancer Institute at the University of Utah###Presenter: – Huntsman Cancer Institute at the University of Utah
### she/her/hers12:00 PM – 12:15 PM CT
8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Discussion
12:00 PM – 12:15 PM CT
Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – The University of Texas MD Anderson Cancer Center
Panelist: – Huntsman Cancer Institute at the University of Utah
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Panelist###Associate Professor###The University of Texas MD Anderson Cancer Center###Panelist: – The University of Texas MD Anderson Cancer Center
### @@@ Heloisa Soares, MD, PhD (she/her/hers) – Huntsman Cancer Institute at the University of Utah ### 1880692###Panelist###Associate Professor###Huntsman Cancer Institute at the University of Utah###Panelist: – Huntsman Cancer Institute at the University of Utah
### she/her/hers12:15 PM – 1:15 PM CT
Lunch
12:15 PM – 1:15 PM CT
Lunch
1:15 PM – 2:00 PM CT
Session 11: Advances in Neuroendocrine Tumors (NETs)
1:15 PM – 2:00 PM CT
Session 11: Advances in Neuroendocrine Tumors (NETs)Presenter: – The University of Texas MD Anderson Cancer Center
Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Presenter###Associate Professor###The University of Texas MD Anderson Cancer Center###Presenter: – The University of Texas MD Anderson Cancer Center
### 2:00 PM – 2:15 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX
2:00 PM – 2:15 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOXPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 2:15 PM – 2:30 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX
2:15 PM – 2:30 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOXPresenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Presenter###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Presenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 2:30 PM – 2:45 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - Discussion
2:30 PM – 2:45 PM CT
Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – MD Anderson Cancer Center, The University of Texas
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Panelist###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Panelist###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Panelist: – MD Anderson Cancer Center, The University of Texas
### 2:45 PM – 3:15 PM CT
Exhibit Hall
2:45 PM – 3:15 PM CT
Exhibit Hall
3:15 PM – 4:00 PM CT
15 - Session 13: The Pillars of Cancer Wellness
3:15 PM – 4:00 PM CT
Session 13: The Pillars of Cancer WellnessPresenter: – Memorial Sloan Kettering Cancer Center
Gary E. Deng, MD, PhD – Memorial Sloan Kettering Cancer Center ### 1699641###Presenter###Medical Director, Integrative Medicine Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 4:00 PM – 4:45 PM CT
14 - Session 14: The Power of Patient Advocacy
4:00 PM – 4:45 PM CT
Session 14: The Power of Patient AdvocacyPresenter: – Fight Colorectal Cancer
Anjee Davis, MPPA (she/her/hers) – Fight Colorectal Cancer ### 1867780###Presenter###President###Fight Colorectal Cancer###Presenter: – Fight Colorectal Cancer
### she/her/hers- Saturday, April 1, 2023
7:45 AM – 8:00 AM CT
Welcome
7:45 AM – 8:00 AM CT
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – University of Chicago
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Co-Chair###Associate Professor of Medicine###University of Chicago###Co-Chair: – University of Chicago
### she/her/hers8:00 AM – 8:15 AM CT
15 - Session 15: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Yes
8:00 AM – 8:15 AM CT
Session 15: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - YesPresenter: – Northwell Health Cancer Institute
Joseph Herman, MD, MSc, MHCM (he/him/his) – Northwell Health Cancer Institute ### 1849663###Presenter###Director of Clinical Research###Northwell Health Cancer Institute###Presenter: – Northwell Health Cancer Institute
### he/him/his8:15 AM – 8:30 AM CT
15 - Session 15: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - No
8:15 AM – 8:30 AM CT
Session 15: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - NoPresenter: – Columbia University Irving Medical Center
Lisa Kachnic, MD (she/her/hers) – Columbia University Irving Medical Center ### 1849664###Presenter###Professor and Chair, Department of Radiation Oncology###Columbia University Irving Medical Center###Presenter: – Columbia University Irving Medical Center
### she/her/hers8:30 AM – 8:45 AM CT
15 - Session 15: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Discussion
8:30 AM – 8:45 AM CT
Session 15: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Session Moderator: – University of Chicago
Panelist: – Northwell Health Cancer Institute
Panelist: – Columbia University Irving Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Session Moderator###Associate Professor of Medicine###University of Chicago###Session Moderator: – University of Chicago
### she/her/hers @@@ Joseph Herman, MD, MSc, MHCM (he/him/his) – Northwell Health Cancer Institute ### 1849663###Panelist###Director of Clinical Research###Northwell Health Cancer Institute###Panelist: – Northwell Health Cancer Institute
### he/him/his @@@ Lisa Kachnic, MD (she/her/hers) – Columbia University Irving Medical Center ### 1849664###Panelist###Professor and Chair, Department of Radiation Oncology###Columbia University Irving Medical Center###Panelist: – Columbia University Irving Medical Center
### she/her/hers8:45 AM – 9:30 AM CT
16 - Session 16: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment Strategies
8:45 AM – 9:30 AM CT
Session 16: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment StrategiesPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 9:30 AM – 10:30 AM CT
An Exelixis Product for the Clinical Management of HCC. Speaker: Amit Mahipal, MBBS, MPH
9:30 AM – 10:30 AM CT
Non-CME Innovation Theater (Sponsored by Exelixis)
10:30 AM – 10:45 AM CT
Exhibit Hall
10:30 AM – 10:45 AM CT
Exhibit Hall
10:45 AM – 11:30 AM CT
Session 17: Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma
10:45 AM – 11:30 AM CT
Session 17: Evaluating Current and Emerging Targeted Therapies in Hepatocellular CarcinomaPresenter: – Memorial Sloan Kettering Cancer Center
Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center ### 697827###Presenter###Professor###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 11:30 AM – 12:00 PM CT
Exhibit Hall
11:30 AM – 12:00 PM CT
Exhibit Hall
12:00 PM – 12:45 PM CT
23 - Session 18: Significance of Cancer Genetics
12:00 PM – 12:45 PM CT
Session 18: Significance of Cancer GeneticsPresenter: – University of Chicago
Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Presenter###Associate Professor of Medicine###University of Chicago###Presenter: – University of Chicago
### she/her/hers12:45 PM – 1:30 PM CT
21 - Session 19: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and Gastric
12:45 PM – 1:30 PM CT
Session 19: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and GastricPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
###
